James Shipley named CMO of Concert Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Concert Pharmaceuticals, a clinical-stage biotech company, has named Dr James Shipley chief medical officer. In the newly created position, he will be responsible for clinical research, clinical operations, regulatory affairs, quality assurance and clinical pharmacology. Dr Shipley has more than 15 years' industry experience, having previously served as senior vice-president of clinical development, medical and regulatory affairs at Indevus Pharmaceuticals (which was acquired by Endo Pharmaceuticals in 2009). Concert has also promoted Dr Robert Silverman to senior vice-president and general counsel. He joined the company in January 2007 as vice-president and general counsel.